Discover Oncology

SEP 8, 2026 · JOURNAL ARTICLE

Translational advances in p53 targeted cancer therapy from molecular mechanisms to clinical application

Discover Oncology

A narrative review evaluating translational barriers to p53-targeted therapy, raising mechanistic questions and proposing future directions rather than reporting a new trial result or establishing clinical efficacy.

SEP 7, 2026 · JOURNAL ARTICLE

Clinical translation of CLDN18.2 and FGFR2b targeting in gastric cancer through assay thresholds and combination strategies

Discover Oncology

A narrative review synthesizing evidence across randomized trials and translational studies to distinguish established clinical practice from exploratory strategies in gastric cancer biomarker-directed therapy.

SEP 7, 2026 · JOURNAL ARTICLE

Long non-coding RNAs in cancer stem cells and therapeutic resistance

Discover Oncology

This is a narrative review synthesizing mechanistic evidence and preclinical findings about lncRNAs in cancer stem cells, raising questions for investigation rather than reporting clinical trial results or definitive empirical evidence.

SEP 7, 2026 · JOURNAL ARTICLE

Tissue-localized immunoengineering for in situ reprogramming of immune cells in cancer therapy

Discover Oncology

This is a narrative review proposing an emerging paradigm of tissue-localized immunoengineering; it raises conceptual and mechanistic questions rather than reporting original empirical evidence or clinical outcomes.

SEP 5, 2026 · JOURNAL ARTICLE

Keratin conversion signature (KRT13/KRT4) defines a high-risk pancreatic cancer subtype with extensive malignant phenotypes

Discover Oncology

A novel biomarker derived from retrospective cohort data with validation in two independent datasets, showing consistent association with overall survival in pancreatic cancer, but lacking mechanistic validation or clinical intervention trials to establish actionability.

SEP 5, 2026 · JOURNAL ARTICLE

Integrated single-cell and bulk RNA sequencing analysis reveals a TPM1-positive myCAF-associated gene signature predicting pancreatic cancer prognosis

Discover Oncology

This is a retrospective computational study integrating public datasets to construct a prognostic risk model; it lacks independent prospective validation and the authors explicitly state the model requires further validation in diverse clinical subgroups and across patient populations.

SEP 4, 2026 · JOURNAL ARTICLE

Advances in regenerative medicine and their impact on cancer therapy and tumor microenvironment modulation

Discover Oncology

A narrative review synthesizing recent advances in regenerative medicine for cancer therapy, identifying unresolved controversies and providing recommendations for translational research and trial design, but not reporting original research data or clinical outcomes.

AUG 18, 2026 · JOURNAL ARTICLE

Comprehensive multi-omics landscape exploration and functional characterization of TACSTD2 throughout pan-cancer

Discover Oncology

A comprehensive pan-cancer bioinformatic and expression profiling study identifying TACSTD2 as a potential biomarker and therapeutic target, but lacking clinical validation or mechanistic proof of causation.